Similarly, stage III or IV ovarian cancer patients with tumors that were BRCA1/2m had significantly better OS than patients with BRCA1/2 wt tumors of the same stage (HR = 0.64 (95% CI = 0.55–0.75)) (Supplementary Figure 1(g)). The gene discussed is BRCA1; the disease is ovarian carcinoma.